Question pretext
The response is mandatory.
Literal question
Which one?
Categories
| Value | Category | Cases | |
|---|---|---|---|
| Evolocumab | Evolocumab (Repatha) 140 mg | 23 |
56.1%
|
| Alirocumab | Alirocumab (Praluent) | 18 |
43.9%
|
| 1 | Inclisiran (Leqvio) 284 mg | 0 |
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.